Oxford Biomedica PLC Cantor Fitzgerald Healthcare Conference 2017
September 25 2017 - 4:46AM
RNS Non-Regulatory
TIDMOXB
Oxford Biomedica PLC
25 September 2017
Oxford BioMedica to Present at Cantor Fitzgerald Healthcare
Conference 2017, New York
Oxford, UK - 25 September 2017: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE:OXB), a leading gene and cell
therapy group, today announces that Kyriacos Mitrophanous, Chief
Scientific Officer, will be presenting at the Cantor Fitzgerald
Healthcare Conference in New York on Wednesday 27 September at
16:35 Eastern Time. Stuart Paynter, Chief Financial Officer will
also be attending the event.
- Ends -
For further information, please
contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Stuart Paynter, Chief Financial
Officer
Consilium Strategic Communications Tel: +44 (0)20
Mary-Jane Elliott/Matthew Neal/Philippa 3709 5700
Gardner/Laura Thornton/Rosie Phillips
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, Orchard
Therapeutics and Immune Design, through which it has long-term
economic interests in other potential gene and cell therapy
products. Oxford BioMedica is based across several locations in
Oxfordshire, UK and employs more than 280 people. Further
information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALIFSTAFIEFID
(END) Dow Jones Newswires
September 25, 2017 04:46 ET (08:46 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024